Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP & General Mgr, Industrial | December 09, 2025 | December 11, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date December 09, 2025 · Filed December 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,673 |
Reported balance
After 2025-12-09 transaction · row 1
1 source rowRow 1 · 2025-12-09 · Tax withholding · Disposed 2,552 · Balance 21,673 |
| Common StockSEC Table I · non-derivative | IndirectBy 2025 GRAT | 12,376 |
Reported balance
Holding disclosure · report date 2025-12-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 12,376 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 1,129 |
Reported balance
Holding disclosure · report date 2025-12-09 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,129 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 09, 2025 Filed Dec 11, 2025 21:34 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 2,552 | $701.51 | $1,790,253.52 |
DisclosureSEC source: 0001411984-25-000007 · edgardoc.xml · nonDerivative · entry 1 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,673 Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 21:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 1,906 | $712.94 | $1,358,863.64 |
DisclosureSEC source: 0001411984-25-000005 · edgardoc.xml · nonDerivative · entry 2 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,225 Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 21:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 18,315 | $0.00 Strike: $726.71 | $0.00 |
DisclosureSEC source: 0001411984-25-000005 · edgardoc.xml · derivative · entry 5 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,315 Underlying: Common Stock · 18,315 shares Expires 2035-12-05 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 21:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 3,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001411984-25-000005 · edgardoc.xml · nonDerivative · entry 1 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,131 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 5, 2027 and 50% on December 5, 2029. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 969 | $730.81 | $708,154.89 |
DisclosureSEC source: 0001968202-24-000142 · edgardoc.xml · nonDerivative · entry 1 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,792 Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 492 | $787.00 | $387,204.00 |
DisclosureSEC source: 0001883850-24-000049 · edgardoc.xml · nonDerivative · entry 2 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,761 Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 13,472 | $0.00 Strike: $771.64 | $0.00 |
DisclosureSEC source: 0001883850-24-000049 · edgardoc.xml · derivative · entry 4 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,472 Underlying: Common Stock · 13,472 shares Expires 2034-12-06 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 3,499 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-24-000049 · edgardoc.xml · nonDerivative · entry 1 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,253 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 6, 2026 and 50% on December 6, 2028. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $951.77 | $190,354.00 |
DisclosureSEC source: 0001968202-24-000066 · edgardoc.xml · nonDerivative · entry 13 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,378 F13 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on February 14, 2024 at prices ranging from $951.61 to $951.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 14, 2024 at each separate price. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 375 | $950.45 | $356,418.75 |
DisclosureSEC source: 0001968202-24-000066 · edgardoc.xml · nonDerivative · entry 12 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,578 F12 · price: Represents volume-weighted average price of sales of 375 shares of Company stock on February 14, 2024 at prices ranging from $950.37 to $950.55. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 14, 2024 at each separate price. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 112 | $949.07 | $106,295.84 |
DisclosureSEC source: 0001968202-24-000066 · edgardoc.xml · nonDerivative · entry 11 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,953 F11 · price: Represents volume-weighted average price of sales of 112 shares of Company stock on February 14, 2024 at prices ranging from $949.02 to $949.14. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 14, 2024 at each separate price. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 150 | $948.70 | $142,305.00 |
DisclosureSEC source: 0001968202-24-000066 · edgardoc.xml · nonDerivative · entry 10 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,065 F10 · price: Represents volume-weighted average price of sales of 150 shares of Company stock on February 14, 2024 at prices ranging from $948.13 to $948.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 14, 2024 at each separate price. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 240 | $947.81 | $227,474.40 |
DisclosureSEC source: 0001968202-24-000066 · edgardoc.xml · nonDerivative · entry 9 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,215 F9 · price: Represents volume-weighted average price of sales of 240 shares of Company stock on February 14, 2024 at prices ranging from $947.77 to $947.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 14, 2024 at each separate price. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 95 | $945.81 | $89,851.95 |
DisclosureSEC source: 0001968202-24-000066 · edgardoc.xml · nonDerivative · entry 8 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,455 F8 · price: Represents volume-weighted average price of sales of 95 shares of Company stock on February 14, 2024 at prices ranging from $945.66 to $945.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 14, 2024 at each separate price. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 620 | $944.30 | $585,466.00 |
DisclosureSEC source: 0001968202-24-000066 · edgardoc.xml · nonDerivative · entry 7 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,550 F7 · price: Represents volume-weighted average price of sales of 620 shares of Company stock on February 14, 2024 at prices ranging from $944.29 to $944.30. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 14, 2024 at each separate price. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,691 | $943.51 | $2,538,985.41 |
DisclosureSEC source: 0001968202-24-000066 · edgardoc.xml · nonDerivative · entry 6 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,170 F6 · price: Represents volume-weighted average price of sales of 2,691 shares of Company stock on February 14, 2024 at prices ranging from $943.23 to $943.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 14, 2024 at each separate price. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 275 | $941.41 | $258,887.75 |
DisclosureSEC source: 0001968202-24-000066 · edgardoc.xml · nonDerivative · entry 5 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,861 F5 · price: Represents volume-weighted average price of sales of 275 shares of Company stock on February 14, 2024 at prices ranging from $941.09 to $941.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 14, 2024 at each separate price. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,261 | $940.44 | $4,007,214.84 |
DisclosureSEC source: 0001968202-24-000066 · edgardoc.xml · nonDerivative · entry 4 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,136 F4 · price: Represents volume-weighted average price of sales of 4,261 shares of Company stock on February 14, 2024 at prices ranging from $940.06 to $940.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 14, 2024 at each separate price. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 750 | $939.60 | $704,700.00 |
DisclosureSEC source: 0001968202-24-000066 · edgardoc.xml · nonDerivative · entry 3 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,397 F3 · price: Represents volume-weighted average price of sales of 750 shares of Company stock on February 14, 2024 at prices ranging from $939.39 to $939.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 14, 2024 at each separate price. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 226 | $938.13 | $212,017.38 |
DisclosureSEC source: 0001968202-24-000066 · edgardoc.xml · nonDerivative · entry 2 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,147 F2 · price: Represents volume-weighted average price of sales of 226 shares of Company stock on February 14, 2024 at prices ranging from $938.00 to $938.45. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 14, 2024 at each separate price. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 439 | $937.94 | $411,755.66 |
DisclosureSEC source: 0001968202-24-000066 · edgardoc.xml · nonDerivative · entry 1 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,373 F1 · price: Represents volume-weighted average price of sales of 439 shares of Company stock on February 14, 2024 at prices ranging from $937.86 to $937.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 14, 2024 at each separate price. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 23,125 | $0.00 Strike: $381.40 | $0.00 |
DisclosureSEC source: 0001968202-24-000064 · edgardoc.xml · derivative · entry 8 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,125 shares Expires 2028-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 12,250 | $0.00 Strike: $372.46 | $0.00 |
DisclosureSEC source: 0001968202-24-000064 · edgardoc.xml · derivative · entry 7 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2029-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 16,341 | $951.68 | $15,551,402.88 |
DisclosureSEC source: 0001968202-24-000064 · edgardoc.xml · nonDerivative · entry 4 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,812 Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 23,125 | $381.40 | $8,819,875.00 |
DisclosureSEC source: 0001968202-24-000064 · edgardoc.xml · nonDerivative · entry 3 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 8,600 | $951.68 | $8,184,448.00 |
DisclosureSEC source: 0001968202-24-000064 · edgardoc.xml · nonDerivative · entry 2 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,028 Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 12,250 | $372.46 | $4,562,635.00 |
DisclosureSEC source: 0001968202-24-000064 · edgardoc.xml · nonDerivative · entry 1 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,628 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 669 | $844.09 | $564,696.21 |
DisclosureSEC source: 0001883850-23-000091 · edgardoc.xml · nonDerivative · entry 4 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,378 Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 2,552 | $844.09 | $2,154,117.68 |
DisclosureSEC source: 0001883850-23-000091 · edgardoc.xml · nonDerivative · entry 3 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,047 Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,473 | $0.00 Strike: $843.79 | $0.00 |
DisclosureSEC source: 0001883850-23-000091 · edgardoc.xml · derivative · entry 7 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,473 Underlying: Common Stock · 11,473 shares Expires 2033-12-08 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 3,199 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-23-000091 · edgardoc.xml · nonDerivative · entry 2 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,599 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 8, 2025 and 50% on December 8, 2027. Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 1,108 | $843.79 | $934,919.32 |
DisclosureSEC source: 0001883850-23-000091 · edgardoc.xml · nonDerivative · entry 1 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,400 Read SEC document |
| August 24, 2023 Filed Aug 25, 2023 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,534 | $844.27 | $2,139,380.18 |
DisclosureSEC source: 0001968202-23-000028 · edgardoc.xml · nonDerivative · entry 12 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,508 F8 · price: Represents volume-weighted average price of sales of 2,534 shares of Company stock on August 24, 2023 at prices ranging from $844.02 to $844.46. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 24, 2023 at each separate price. Read SEC document |
| August 24, 2023 Filed Aug 25, 2023 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 759 | $843.31 | $640,072.29 |
DisclosureSEC source: 0001968202-23-000028 · edgardoc.xml · nonDerivative · entry 11 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,042 F7 · price: Represents volume-weighted average price of sales of 759 shares of Company stock on August 24, 2023 at prices ranging from $843.04 to $843.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 24, 2023 at each separate price. Read SEC document |
| August 24, 2023 Filed Aug 25, 2023 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 617 | $842.66 | $519,921.22 |
DisclosureSEC source: 0001968202-23-000028 · edgardoc.xml · nonDerivative · entry 10 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,801 F6 · price: Represents volume-weighted average price of sales of 617 shares of Company stock on August 24, 2023 at prices ranging from $842.28 to $842.77. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 24, 2023 at each separate price. Read SEC document |
| August 24, 2023 Filed Aug 25, 2023 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 363 | $841.15 | $305,337.45 |
DisclosureSEC source: 0001968202-23-000028 · edgardoc.xml · nonDerivative · entry 9 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,418 F5 · price: Represents volume-weighted average price of sales of 363 shares of Company stock on August 24, 2023 at prices ranging from $841.03 to $841.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 24, 2023 at each separate price. Read SEC document |
| August 24, 2023 Filed Aug 25, 2023 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 46 | $840.74 | $38,674.04 |
DisclosureSEC source: 0001968202-23-000028 · edgardoc.xml · nonDerivative · entry 8 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,781 Read SEC document |
| August 24, 2023 Filed Aug 25, 2023 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 148 | $839.28 | $124,213.44 |
DisclosureSEC source: 0001968202-23-000028 · edgardoc.xml · nonDerivative · entry 7 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,827 F4 · price: Represents volume-weighted average price of sales of 148 shares of Company stock on August 24, 2023 at prices ranging from $839.08 to $839.37. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 24, 2023 at each separate price. Read SEC document |
| August 24, 2023 Filed Aug 25, 2023 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 667 | $838.37 | $559,192.79 |
DisclosureSEC source: 0001968202-23-000028 · edgardoc.xml · nonDerivative · entry 6 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,975 F3 · price: Represents volume-weighted average price of sales of 667 shares of Company stock on August 24, 2023 at prices ranging from $838.06 to $838.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 24, 2023 at each separate price. Read SEC document |
| August 24, 2023 Filed Aug 25, 2023 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 300 | $837.53 | $251,259.00 |
DisclosureSEC source: 0001968202-23-000028 · edgardoc.xml · nonDerivative · entry 5 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,642 Read SEC document |
| August 24, 2023 Filed Aug 25, 2023 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 625 | $836.32 | $522,700.00 |
DisclosureSEC source: 0001968202-23-000028 · edgardoc.xml · nonDerivative · entry 4 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,942 F2 · price: Represents volume-weighted average price of sales of 625 shares of Company stock on August 24, 2023 at prices ranging from $836.10 to $836.53. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 24, 2023 at each separate price. Read SEC document |
| August 24, 2023 Filed Aug 25, 2023 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 138 | $835.67 | $115,322.46 |
DisclosureSEC source: 0001968202-23-000028 · edgardoc.xml · nonDerivative · entry 3 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,567 F1 · price: Represents volume-weighted average price of sales of 138 shares of Company stock on August 24, 2023 at prices ranging from $835.58 to $835.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 24, 2023 at each separate price. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 23,125 | $0.00 Strike: $381.40 | $0.00 |
DisclosureSEC source: 0001968202-23-000028 · edgardoc.xml · derivative · entry 15 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,125 Underlying: Common Stock · 23,125 shares Expires 2028-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 16,928 | $842.66 | $14,264,548.48 |
DisclosureSEC source: 0001968202-23-000028 · edgardoc.xml · nonDerivative · entry 2 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,705 Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 23,125 | $381.40 | $8,819,875.00 |
DisclosureSEC source: 0001968202-23-000028 · edgardoc.xml · nonDerivative · entry 1 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 14,019 | $0.00 Strike: $726.53 | $0.00 |
DisclosureSEC source: 0001883850-22-000137 · edgardoc.xml · derivative · entry 3 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,019 Underlying: Common Stock · 14,019 shares Expires 2032-12-16 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 3,798 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-22-000137 · edgardoc.xml · nonDerivative · entry 1 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,884 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 16, 2024 and 50% on December 16, 2026. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 492 | $753.28 | $370,613.76 |
DisclosureSEC source: 0001883850-22-000118 · edgardoc.xml · nonDerivative · entry 1 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,086 Read SEC document |
| November 23, 2022 Filed Nov 25, 2022 18:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $748.17 | $748.17 |
DisclosureSEC source: 0001883850-22-000098 · edgardoc.xml · nonDerivative · entry 16 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,578 Read SEC document |
| November 23, 2022 Filed Nov 25, 2022 18:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 629 | $747.28 | $470,039.12 |
DisclosureSEC source: 0001883850-22-000098 · edgardoc.xml · nonDerivative · entry 15 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,579 F13 · price: Represents volume-weighted average price of sales of 629 shares of Company stock on November 23, 2022 at prices ranging from $747.05 to $747.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 23, 2022 at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.